CKD-501

DRUG5 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

HealthyHealthy Male VolunteersLiver DysfunctionRenal ImpairmentType 2 DiabetesType 2 Diabetes Mellitus

Phase 1

Drug Interaction Between CKD-501 and Metformin

CompletedNCT01005160

Chong Kun Dang PharmaceuticalHealthy Male Volunteers

Start: 2009-10-31End: 2010-02-28Target: 24Updated: 2011-01-12

Drug-drug Interaction Study(CKD-501, Amlodipine)

CompletedNCT01341392

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus

Start: 2011-04-30End: 2011-08-31Updated: 2011-08-15

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

CompletedNCT02005744

Chong Kun Dang PharmaceuticalLiver Dysfunction

Start: 2014-03-31End: 2016-02-29Updated: 2016-07-04

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

CompletedNCT02007941

Chong Kun Dang PharmaceuticalHealthy, Renal Impairment

Start: 2014-04-30End: 2015-04-30Updated: 2016-12-06

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150

CompletedNCT04334213

Chong Kun Dang PharmaceuticalType 2 Diabetes

Start: 2020-05-07End: 2020-08-05Updated: 2020-10-30

Related Papers

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects

Translational and Clinical Pharmacology2023-01-012 citations

Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.

2015-07-0710 citations

Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.

2012-07-0213 citations